Skip to main content

Advertisement

SpringerLink
Log in

Managing Risks of Neoplasia in Inflammatory Bowel Disease

  • Inflammatory Bowel Disease (SB Hanauer, Section Editor)
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Inflammatory bowel disease (IBD) has been linked with a variety of intestinal and extraintestinal cancers. This review summarizes the latest literature with regard to which cancers are truly linked with IBD and which are not, the absolute and relative risks of these cancers, how medications commonly prescribed for IBD affect this risk, and finally strategies for managing these risks. Physicians and health professionals may find this information useful for counseling and educating patients as well as for improving patient care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–8. e1621-1625. Important prospective study establishing risk of non-melanoma skin cancer in people with inflammatory bowel disease on thiopruines.

    Article  PubMed  CAS  Google Scholar 

  2. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8(3):268–74.

    Article  PubMed  Google Scholar 

  3. Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Int J Cancer. 1995;60(3):330–3.

    Article  PubMed  CAS  Google Scholar 

  4. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67(7):2015–9.

    Article  PubMed  CAS  Google Scholar 

  5. • Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. Jul 30 2011. Important population-based study establishing risk of non-melanoma skin cancer in people with inflammatory bowel disease on thiopruines.

  6. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141(5):1612–20.

    Article  PubMed  Google Scholar 

  7. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. preventive. Rockville (MD); 2009.

  8. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12(38):6167–71.

    PubMed  Google Scholar 

  9. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631–6.

    Article  PubMed  Google Scholar 

  10. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case–control study. Gastroenterology. 2009;136(2):451–8.

    Article  PubMed  Google Scholar 

  11. Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: a large case–control study. Inflamm Bowel Dis. 2009;15(11):1621–9.

    Article  PubMed  CAS  Google Scholar 

  12. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(5):598–605.

    Article  PubMed  CAS  Google Scholar 

  13. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343(8908):1249–52.

    Article  CAS  Google Scholar 

  14. Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc. 2009;69(7):1299–310.

    Article  PubMed  Google Scholar 

  15. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. May 28 2010;59(20):630–32.

  16. Shaukat A, Virnig DJ, Howard D, Sitaraman SV, Liff JM, Lederle FA. Crohn’s disease and small bowel adenocarcinoma: a population-based case–control study. Cancer Epidemiol Biomark Prev. 2011;20(6):1120–3.

    Article  CAS  Google Scholar 

  17. Jess T, Loftus Jr EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130(4):1039–46.

    Article  PubMed  Google Scholar 

  18. Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn’s disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis. 2005;11(9):828–32.

    Article  PubMed  Google Scholar 

  19. Piton G, Cosnes J, Monnet E, et al. Risk factors associated with small bowel adenocarcinoma in Crohn’s disease: a case–control study. Am J Gastroenterol. 2008;103(7):1730–6.

    Article  PubMed  Google Scholar 

  20. Soyer P, Hristova L, Boudghene F, et al. Small bowel adenocarcinoma in Crohn disease: CT-enterography features with pathological correlation. Abdom Imaging. Jun 14 2011.

  21. Solem CA, Harmsen WS, Zinsmeister AR, Loftus Jr EV. Small intestinal adenocarcinoma in Crohn’s disease: a case–control study. Inflamm Bowel Dis. 2004;10(1):32–5.

    Article  PubMed  Google Scholar 

  22. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–9.

    Article  PubMed  Google Scholar 

  23. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100(12):2724–9.

    Article  PubMed  Google Scholar 

  24. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23(8):1097–104.

    Article  PubMed  CAS  Google Scholar 

  25. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228–33.

    Article  PubMed  CAS  Google Scholar 

  26. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35.

    Article  PubMed  CAS  Google Scholar 

  27. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120(6):1356–62.

    Article  PubMed  CAS  Google Scholar 

  28. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48–54.

    Article  PubMed  Google Scholar 

  29. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53(12):1813–6.

    Article  PubMed  CAS  Google Scholar 

  30. Velayos FS, Loftus Jr EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study. Gastroenterology. 2006;130(7):1941–9.

    Article  PubMed  Google Scholar 

  31. •• Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74. 774 e741-744; quiz e712-743. Important comprehensive review regarding colorectal cancer detection and prevention in inflammatory bowel disease.

    Article  PubMed  Google Scholar 

  32. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:10–4.

    Article  PubMed  CAS  Google Scholar 

  33. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345–53.

    Article  PubMed  CAS  Google Scholar 

  34. Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn’s colitis: a case–control study. Inflamm Bowel Dis. 2006;12(6):491–6.

    Article  PubMed  Google Scholar 

  35. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005;100(6):1354–6.

    Article  PubMed  CAS  Google Scholar 

  36. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371–85.

    Article  PubMed  Google Scholar 

  37. Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63(4):546–57.

    Article  PubMed  Google Scholar 

  38. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89.

    Article  PubMed  Google Scholar 

  39. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544–60.

    Article  PubMed  Google Scholar 

  40. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(3):314–21.

    Article  PubMed  Google Scholar 

  41. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60(3):334–9.

    Article  PubMed  Google Scholar 

  42. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103(9):2342–9.

    Article  PubMed  Google Scholar 

  43. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256–60.

    Article  PubMed  CAS  Google Scholar 

  44. Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007;39(3):216–21.

    Article  PubMed  CAS  Google Scholar 

  45. Beaugerie L, Brousse N, Bouvier AM, et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the CESAME cohort. Gastroenterology. 2008;134(A):116–7.

    Google Scholar 

  46. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121(5):1080–7.

    Article  PubMed  CAS  Google Scholar 

  47. Loftus Jr EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95(9):2308–12.

    Article  PubMed  Google Scholar 

  48. Mir-Madjlessi SH, Farmer RG, Easley KA, Beck GJ. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer. 1986;58(7):1569–74.

    Article  PubMed  CAS  Google Scholar 

  49. NCI. 2011; http://seer.cancer.gov/statfacts/html/lymph.html.

  50. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–5.

    Article  PubMed  CAS  Google Scholar 

  51. • Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25. Important population-based study establishing the risk of lymphoma in thiopruine users.

    Article  PubMed  CAS  Google Scholar 

  52. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–81.

    Article  PubMed  CAS  Google Scholar 

  53. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41. e31.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. University of California, San Francisco, Center for Crohn’s and Colitis, 2330 Post Street, Suite 610, San Francisco, CA, 94115, USA

    Fernando Velayos

Authors
  1. Fernando Velayos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Velayos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Velayos, F. Managing Risks of Neoplasia in Inflammatory Bowel Disease. Curr Gastroenterol Rep 14, 174–180 (2012). https://doi.org/10.1007/s11894-012-0247-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-012-0247-7

Keywords

Search

Navigation